z-logo
Premium
S2‐02–05: Anti‐abeta antibodies in Alzheimer's disease mouse models
Author(s) -
Golde Todd E.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.280
Subject(s) - immunotherapy , antibody , immunology , gliosis , epitope , medicine , senile plaques , clearance , neuroscience , active immunotherapy , disease , alzheimer's disease , biology , pathology , immune system , urology
calpain activation with A plaque formation in brains from both AD patients and transgenic (Tg) mice overexpressing amyloid precursor protein (APP). The mice also exhibited axonal termini dynamically misdirected to calpain activation-positive A plaques. Consistently, cerebrospinal fluids from Tg mice and AD patients contained greater quantity of calpain-cleaved spectrin than controls. Genetic deficiency of calpastatin (CS), calpain-specific inhibitor protein, augmented A amyloidosis, tau phosphorylation, microgliosis, somato-dendritic dystrophy and mortality in APP-Tg mice. In contrast, brain-specific CS overexpression resulted in opposite phenotypes. Conclusions: These observations indicate that calpain activation may underlie A -triggered pathological cascade and thus shall become a relevant pharmacological target in the treatment of AD.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom